This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amicus Delays U.S. Approval Filing for Fabry Disease Drug

CRANBURY, NJ ( TheStreet) -- The U.S. Food and Drug Administration refused a request from Amicus Therapeutics (FOLD - Get Report) to amend the statistical plan for a failed phase III study of its experimental Fabry disease drug Amigal. As a result, Amicus is delaying the U.S. approval filing for Amigal until late 2014 or early 2015 -- after data from another phase III study is completed.

Amicus shares fell 22% to $2.50 in early Monday trading.

Last December, Amicus announced disappointing six-month results from a phase III study of Amigal in patients with Fabry disease. Forty-one percent of Amigal patients were counted as responders (meaning they had a 50% decrease in GL3 in their kidneys. By comparison, 28% of placebo patients were responded. The response trend clearly favored Amigal but the difference was not statistically significant.

Amicus met with FDA hoping to convince regulators to allow changes to the study to review Amigal's efficacy based on longer-term (12 months) response rates, as well as in certain subgroups of patients with higher baseline levels of GL3.

On Monday, Amicus said FDA agreed to the changes in the study but regulator also insisted that from a regulatory standpoint, the study would still be considered a failure. This prevents Amicus and partner GlaxoSmithKline (GSK - Get Report) from seeking FDA approval until more Amigal data is compiled.

The two companies are conducting a second phase III study in which Fabry patients are switched from a currently approved therapy to Amigal. Results from this study are expected in the first half of 2014. Even if the study is positive, Amicus cautioned that a U.S. filing won't be completed until another meeting is held with FDA in the second half of 2014.

Twelve-month data from the first phase III study are expected in the fourth quarter of this year.

Amicus has enough cash on hand to continue operations into the second half of 2014.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
FOLD $10.90 -0.59%
GSK $47.15 0.28%
AAPL $125.45 1.80%
FB $82.86 -0.53%
GOOG $551.16 0.51%


DOW 17,996.19 +283.53 1.60%
S&P 500 2,084.31 +23.29 1.13%
NASDAQ 4,937.5940 +46.3750 0.95%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs